ReviewAmerican journal of cancer research2026
PAX1/JAM3 methylation-a novel biomarker for early detection and accurate management of cervical adenocarcinoma.
Review in American journal of cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cervical adenocarcinoma is a relatively special pathological type of cervical cancer. Due to its hidden location, low sensitivity of traditional cytology, and insufficient specificity of high-risk human papillomavirus (HR-HPV) detection, it is used in early diagnosis and accurate management. It presents huge challenges. Epigenetic markers represented by DNA methylation provide new breakthroughs in the diagnosis and treatment of cervical cancer. Among them, the dual-gene methylation detection of pairing box gene 1 (PAX1) and junction adhesion molecule 3 (JAM3) has become a new molecular marker with broad prospects because of its significant hypermethylation status in cervical adenocarcinoma tissues and excellent diagnostic sensitivity and specificity. This review summarizes the biological characteristics and carcinogenic mechanism of PAX1/JAM3 double gene methylation and the latest research progress in cervical adenocarcinoma screening and diagnosis, and discusses its application value, existing challenges and future development directions in order to provide new insights and directions for the pathogenesis research and clinical diagnosis and treatment strategies of cervical adenocarcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.